戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rization with activity comparable to that of combretastatin A-1 (3a), the phosphorylated derivative (
2 activity, and the benzophenone derivative of combretastatin A-1 was therefore synthesized.
3 t, the corresponding carbonate derivative of combretastatin A-4 (13) was unstable in aqueous environm
4 eries of cis- and trans-stilbenes related to combretastatin A-4 (1a), with a variety of substituents
5 ombretum caffrum) antineoplastic constituent combretastatin A-4 (1b) directed at maintaining the (Z)-
6 y crystal structure of the 3'-O-phosphate of combretastatin A-4 (1b) was successfully elucidated.
7 nding of colchicine to tubulin comparable to combretastatin A-4 (1b).
8 sent SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focused mainly on the olefi
9 served with the phosphorylated derivative of combretastatin A-4 (1d), phosphate 3d retained detectabl
10 ombretum caffrum) antineoplastic constituent combretastatin A-4 (3b) led to the discovery of a potent
11  phenolic anticancer drugs etoposide (6) and combretastatin A-4 (7) were attached to the Z-val-cit-p-
12 y-1H-indoles were obtained as a new class of combretastatin A-4 (CA-4) analogues via a convenient ult
13 eric derivatives designed as cis-constrained combretastatin A-4 (CA-4) analogues were synthesized and
14                                 Cis-stilbene combretastatin A-4 (CA-4) and a large group of its deriv
15                    Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support
16 erocycles in place of the cis double bond in combretastatin A-4 (CA-4) are described.
17                                              Combretastatin A-4 (CA-4) in phosphate and serine pro-dr
18                                              Combretastatin A-4 (CA-4) is a naturally occurring agent
19 iguration afforded by the cis double bond in combretastatin A-4 (CA-4).
20 embly with IC50 values comparable to that of combretastatin A-4 (CA-4).
21 vel 2,5-diaryl-1,3,4-oxadiazoline analogs of combretastatin A-4 (CA-4, 1) were designed, synthesized,
22                                 A prodrug of combretastatin A-4 (CA4) was prepared, CMP-L-CA4, where
23 inoacrylate linker (L), and a cytotoxic drug combretastatin A-4 (CA4).
24 zole scaffold and designed as cis-restricted combretastatin A-4 analogues, was synthesized with the g
25 nt inhibition of tubulin polymerization than combretastatin A-4 and strong binding to the colchicine
26 mitotic natural products podophyllotoxin and combretastatin A-4 and to that of NSC 664171, a particul
27 embranes, which was similar to cisplatin and combretastatin A-4 and without significant toxicity towa
28     Compounds 9i and j were more active than combretastatin A-4 as inhibitors of tubulin polymerizati
29 rowth and, potentially, to better define the combretastatin A-4 binding site on tubulin.
30                             The mechanism of combretastatin A-4 cytotoxicity has now been investigate
31       Incubation of cells for up to 8 h with combretastatin A-4 did not induce the release of lactate
32     The antiangiogenic, tubulin-binding drug combretastatin A-4 exhibits a selective toxicity for pro
33  was detected in cells incubated with 0.1 mM combretastatin A-4 for 24 h.
34 totoxic and antitubulin activity compared to combretastatin A-4 in neuroblastoma cells, showing a bet
35 n was confirmed, and it was more potent than combretastatin A-4 in these assays.
36              Incubation of cells with 0.1 mM combretastatin A-4 induced the conversion (first detecte
37 icate that the selective cytotoxic effect of combretastatin A-4 is mediated by the induction of apopt
38 tected with either the colchicine site agent combretastatin A-4 or with an analog of the antimitotic
39  and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain
40                                              Combretastatin A-4 phosphate (CA4P) is a novel antitumor
41                      Purpose To determine if combretastatin A-4 phosphate disodium (CA4P) can enhance
42 nd is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived
43 del comparable to the activity obtained with combretastatin A-4 phosphate.
44             Compound 1b has been termed the "combretastatin A-4 prodrug", and it is currently undergo
45              This benzophenone derivative of combretastatin A-4 showed remarkable antineoplastic acti
46 expectedly obtained by Jacobsen oxidation of combretastatin A-4 silyl ether (1c --> 3a), and the pare
47             The geometric trans-isomer 3a of combretastatin A-4 was converted to the (1S,2S)- and (1R
48 ion (IC50 = 22 microM, versus 1.2 microM for combretastatin A-4), while 4d was inactive (IC50 > 40 mi
49  structure of a known microtubule inhibitor, combretastatin A-4, Borowiak et al. develop a photoswitc
50 ture of the tubulin polymerization inhibitor combretastatin A-4, the possibility exists that the rati
51                                              Combretastatin A-4-phosphate (CA-4-P) is a tubulin-bindi
52                    The tubulin-binding agent combretastatin A-4-phosphate (CA-4-P), rapidly disrupts
53  In this study the effect of a CA-4 prodrug, combretastatin A-4-phosphate (CA-4-P), was tested in two
54  cancer cells and superior to colchicine and combretastatin A-4.
55 tereoselective synthesis of anticancer agent combretastatin A-4.
56 arison with the potent colchicine site agent combretastatin A-4.
57 aqueous environments and was as cytotoxic as combretastatin A-4.
58 al products colchicine, podophyllotoxin, and combretastatin A-4.
59 to those of colchicine, podophyllotoxin, and combretastatin A-4.
60 al products colchicine, podophyllotoxin, and combretastatin A-4.
61 al products colchicine, podophyllotoxin, and combretastatin A-4.
62  series of carbazole sulfonamides related to Combretastatin A4 (1) were synthesized and evaluated for
63 of either anecortave acetate (300 microg) or combretastatin A4 (1.5 mg).
64 st potent compounds exceeded the activity of combretastatin A4 (CA-4), showing single digit nM IC50 v
65                                              Combretastatin A4 (CA4) phosphate (CA4P) inhibits microt
66     CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized t
67 phorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (
68  small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the f
69 ol was performed 24 hours after injection of combretastatin A4 phosphate (CA4P) in 12 mice.
70 ute effects of the vascular disrupting agent combretastatin A4 phosphate (CA4P) on luciferase-express
71  the effects of the vascular targeting agent combretastatin A4 phosphate (CA4P) on tumor and normal t
72    Vascular-disrupting agents (VDAs) such as combretastatin A4 phosphate (CA4P) selectively disrupt b
73           A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-bind
74 cy of microtubule-disrupting agents, such as combretastatin A4 phosphate (CA4P), in inducing rapid re
75                                 The disodium combretastatin A4 phosphate prodrug is currently undergo
76 ons of the selective vascular-targeting drug combretastatin A4 prodrug (CA4P) or anecortave acetate,
77   In contrast, the vascular disrupting agent combretastatin A4-phosphate, which caused a similar amou
78 e development of one such antivascular drug, combretastatin A4.
79 eries of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and synthesized.
80 tion on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chos
81 xic doses of microtubule-destabilizing agent combretastatin-A4-phosphate (CA4P) inhibit leukemic cell
82 treatment with the vascular targeting agent, combretastatin A4P, or the antiangiogenic agent, contort
83  have developed a modular synthetic route to combretastatin analogs based on a pyrazole core through
84 iogenesis was inhibited after treatment with combretastatin and thalidomide.
85 w assesses the in vitro and in vivo data for combretastatin and the prodrug, and the preliminary data
86                                          The combretastatins are an important class of tubulin-bindin
87  of a new family of macrocyclic analogues of combretastatins B combining oxygenated substituents on t
88                      The vasodisruptive drug combretastatin CA4 also targeted MV selectively but acte
89 D-2 and D-4 as well as a formal synthesis of combretastatin D-1 by a conceptually new route harnessin
90 ld be prepared as a side product en route to combretastatin D-2 by synchronous extrusion of SO2 and C
91                   We report the syntheses of combretastatins D-2 and D-4 as well as a formal synthesi
92                                              Combretastatin has shown activity in phase 1 and phase I
93 arried out to develop a predictive model for combretastatin-like analogues populating the colchicine-
94   COMPARE analysis led to the discovery of a combretastatin-like quinoline-5,8-dione structure that,
95 have synthesized a novel class of cis-locked combretastatins named combreatabenzodiazepines.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。